Brain Tumor Treatments: Chemotherapy
Sponsored By
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Chemotherapy
Please scroll down past the trials to see pages on this site about this topic!

  Treatment Location Last Updated
Details A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Durham, NC USA 07/31/2008
Details A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Omaha, NE USA 07/31/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma Boston, MA USA 07/24/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma Houston, TX USA 07/24/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma New York, NY USA 07/24/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer New York, NY USA 07/24/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer Houston, TX USA 07/24/2008
Details A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer San Antonio, TX USA 07/24/2008
Details PHASE 2, 2-PART, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CT-322 (ANGIOCEPT™) MONOTHERAPY AND COMBINATION THERAPY WITH IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME San Francisco, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Chicago, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Detroit, MI USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Durham, NC USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Charlottesville, VA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Cleveland, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Cleveland, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Hackensack, NJ USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Syracuse, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Chicago, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Los Angeles, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Boston, MA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New Haven, CT USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Buffalo, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Salt Lake City, UT USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Columbus, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Evanston, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Palo Alto, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New York, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Philadelphia, PA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Houston, TX USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Seattle, WA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New York, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Jacksonville, FL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme San Francisco, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Saginaw, MI USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Gainsville, FL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme San Antonio, TX USA 07/03/2008
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Cincinnati, Oh USA 06/04/2008
Details Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients with Malignant Glioma Houston, TX USA 05/28/2008
Details Phase I/II Trial of Irinotecan plus Lenalidomide in Adult Patients with Recurrent Glioblastoma Multiforme Houston, TX USA 05/28/2008
Details A Phase II Study of Bevacizumab (Avastin) Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation San Francisco, CA USA 04/27/2008
Details Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme Houston , TX 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Durham, NC USA 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Charlottesville, VA USA 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme New York, NY USA 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Boston, MA USA 04/27/2008
Details A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme Houston, TX USA 04/16/2008
Details Phase I/II Study of Temozolomide and Intrathecal DepoCyt in Patients with Neoplastic Meningitis Houston, TX USA 04/16/2008
Details A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma Houston, TX USA 04/16/2008
Details Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma Houston, TX USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas New York, NY USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Durham, NC USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Houston, TX USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Los Angeles, CA USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Bethesda, MD USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Boston, MA 04/15/2008
Details Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme Houston, TX USA 04/15/2008
Details A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma Houston, TX USA 04/15/2008
Details A Phase I Dose-Finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients with Recurrent or Refractory Glioma, with or without Concurrent Treatment with Enzyme-Inducing Anticonvulsant Drug Therapy. Houston, TX USA 04/15/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Tampa, FL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Houston, TX USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Akron, OH USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Cleveland, OH 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Springfield, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Goldsboro, NC USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma , OH USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Greenville, SC USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Akron, OH USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Wynnewood, PA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Kingsport, TN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Newark, DE USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Philadelphia, PA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Mobile, AL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Loma Linda, CA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Sacramento, CA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Pomona, CA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Sacramento, CA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Lewes, DE USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Newark, DE USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Jacksonville, FL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Columbus, GA USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Honolula, HI USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Boise, ID USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Maywood, IL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Harvey, IL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Chicago, IL USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma South Bend,, IN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma South Bend, IN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Annapolis, MD USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Detroit, MI USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Royal Oak, MI USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Saint Louis Park, MN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Edina, MN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Robbinsdale, MN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Minneapolis, MN USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Cape Girardeau, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Kansas City, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Saint Louis, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma St Louis, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Joplin, MO USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Omaha, NE USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Concord, NH USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Lebanon, NH USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Voorhees, NJ USA 04/11/2008
Details Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma Marlton, NJ USA